Moomoo AIのまとめ
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have collectively reported beneficial ownership of 5,855,597 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing approximately 9.99% of the company's outstanding shares. The filing, made with the United States Securities and Exchange Commission, indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The ownership percentage is based on the current total of 58,614,593 outstanding shares of Tonix Pharmaceuticals, as reported in the company's Form 8-K filed on January 25, 2024. The report also includes a statement that the reporting persons hold warrants to purchase additional shares, but due to the terms of the Warrants, they can only exercise enough to maintain a 9.9% ownership stake. The filing was completed on February 14, 2024, by Jason Bragg, Chief Financial Officer of Alyeska Investment Group, L.P. and Alyeska Fund GP, LLC, and Anand Parekh individually.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have collectively reported beneficial ownership of 5,855,597 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing approximately 9.99% of the company's outstanding shares. The filing, made with the United States Securities and Exchange Commission, indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The ownership percentage is based on the current total of 58,614,593 outstanding shares of Tonix Pharmaceuticals, as reported in the company's Form 8-K filed on January 25, 2024. The report also includes a statement that the reporting persons hold warrants to purchase additional shares, but due to the terms of the Warrants, they can only exercise enough to maintain a 9.9% ownership stake. The filing was completed on February 14, 2024, by Jason Bragg, Chief Financial Officer of Alyeska Investment Group, L.P. and Alyeska Fund GP, LLC, and Anand Parekh individually.
Alyeska Investment Group, L.P.、Alyeska Fund GP、LLC、およびAnand Parekhは、Tonix Pharmaceuticals Holding Corp.の普通株式約5,855,597株に対する有益所有権を合わせて報告しており、これは同社の発行済み株式の約9.99％に相当します。米国証券取引委員会に提出された申告書には、これらの株式はビジネスの通常コースで取得され、発行人の支配を変更または影響する目的ではないことが示されています。所有割合は、2024年1月25日に同社が提出した8-Kフォームで報告されたTonix Pharmaceutical...すべて展開
Alyeska Investment Group, L.P.、Alyeska Fund GP、LLC、およびAnand Parekhは、Tonix Pharmaceuticals Holding Corp.の普通株式約5,855,597株に対する有益所有権を合わせて報告しており、これは同社の発行済み株式の約9.99％に相当します。米国証券取引委員会に提出された申告書には、これらの株式はビジネスの通常コースで取得され、発行人の支配を変更または影響する目的ではないことが示されています。所有割合は、2024年1月25日に同社が提出した8-Kフォームで報告されたTonix Pharmaceuticalsの発行済み株式合計58,614,593株に基づいています。申告書には、報告者が追加の株式を購入するためのウォラントを保有しているという声明も含まれていますが、ウォラントの条件により、彼らは9.9％の所有権保有を維持するために十分なみの株式の行使しかできません。この申告は、Alyeska Investment Group、L.P.およびAlyeska Fund GP、LLCの最高財務責任者であるJason Braggと、個人的にAnand Parekhによって2024年2月14日に完了されました。
役に立った
役に立たない